ANI Pharmaceuticals
ANIP
28 hedge funds and large institutions have $10.6M invested in ANI Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 14 closing their positions.
903% more call options, than puts
Call options by funds: $4.47M | Put options by funds: $446K
119% more capital invested
Capital invested by funds: $4.84M → $10.6M (+$5.75M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 34 → 28 (-6)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
Top Sellers
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$59K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$38K |
| 3 |
Renaissance Technologies
New York
|
-$36K |
| 4 |
Goldman Sachs
New York
|
-$33K |
| 5 |
D.E. Shaw & Co
New York
|
-$24K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Renaissance Technologies
New York
| – | -$36K | -5,959 | Closed |
|
|
27
Goldman Sachs
New York
| – | -$33K | -5,485 | Closed |
|
|
28
D.E. Shaw & Co
New York
| – | -$24K | -3,927 | Closed |
|
|
GC
29
Guggenheim Capital
Chicago,
Illinois
| – | -$23K | -3,761 | Closed |
|
|
ZIG
30
Zuckerman Investment Group
Chicago,
Illinois
| – | -$15K | -2,509 | Closed |
|
31
Citadel Advisors
Miami,
Florida
| – | -$13K | -2,244 | Closed |
|
32
State Street
Boston,
Massachusetts
| – | -$13K | -2,173 | Closed |
|
33
Citigroup
New York
| – | -$2K | -229 | Closed |
|
34
ClearBridge Investments
New York
| – | -$1K | -25 | Closed |
|
|
DADC
35
D.A. Davidson & Co
Great Falls,
Montana
| – | -$7 | -1 | -4% |
|
36
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$7 | -1 | -25% |
|
37
Creative Planning
Overland Park,
Kansas
| – | +$7 | +1 | New |
|
38
Wells Fargo
San Francisco,
California
| – | +$14 | +2 | +200% |
|
|
AC
39
Alexandria Capital
Arlington,
Virginia
| – | +$50 | +7 | New |
|
ANIP Hedge Fund Activity: Q3 2013 in Review
28 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2013, worth a combined $10.6M — up 119% from $4.84M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ANIP and 9 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Healthcare Value Capital, adding an estimated $1.3M. The largest seller was Nomura Holdings, exiting entirely with an estimated $59K sold.
- 28 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2013, down from 34 in Q2 2013.
- Funds reported $10.6M of ANI Pharmaceuticals stock for Q3 2013, up 119% quarter-over-quarter.
- 9 funds opened new ANI Pharmaceuticals positions in Q3 2013 and 14 closed out, a net change of -5 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2013 was Healthcare Value Capital, an estimated $1.3M added.
- The largest ANI Pharmaceuticals seller in Q3 2013 was Nomura Holdings, an estimated $59K sold.
Based on aggregated 13F filings for Q3 2013.